Graphite Bio, Inc. Profile Avatar - Palmy Investing

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly co…

Biotechnology
US, South San Francisco [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of GRPH's Analysis
CIK: 1815776 CUSIP: 38870X104 ISIN: US38870X1046 LEI: - UEI: -
Secondary Listings
GRPH has no secondary listings inside our databases.